Hib + Meningococcal C vaccine
Brand names: Menitorix
This combined conjugate vaccine provides active immunisation against Haemophilus influenzae type b (Hib) and Neisseria meningitidis group C, used in the routine UK childhood programme.
Vaccines and immunoglobulins are given by national schedule or product-specific guidance: see the UK Green Book (UKHSA) and the product's SmPC.
Clinical monograph
How it works
Capsular polysaccharides from Hib and meningococcal group C are conjugated to a carrier protein, producing a T-cell-dependent immune response with protective antibodies and immunological memory in young children.
Prescribing in practice
- It is contraindicated in those with a confirmed anaphylactic reaction to a previous dose or a vaccine component, and acute febrile illness warrants deferral.
- It should be given at the recommended age according to the routine schedule for optimal protection.
- Administer intramuscularly and follow the relevant Green Book chapter, the SPC and current prescribing references for timing and co-administration.
Monitoring
Routine antibody monitoring is not required; observe after vaccination for immediate hypersensitivity and ensure scheduled doses are given.
Counselling the patient
- Keep your child's vaccinations up to date according to the routine schedule.
- Mild fever and injection-site soreness can occur and usually settle within a day or two.
- Seek advice if your child is unwell with a high fever after vaccination.
Evidence & guidelines
The Hib/MenC conjugate vaccine is part of the routine UK childhood immunisation schedule as set out in the Green Book.
Reference: UK Green Book; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.